MARKET

PDSB

PDSB

Pds Biotechnology Corporation
NASDAQ
3.040
-0.150
-4.70%
After Hours: 3.020 -0.02 -0.66% 18:14 09/23 EDT
OPEN
3.100
PREV CLOSE
3.190
HIGH
3.140
LOW
3.010
VOLUME
117.63K
TURNOVER
0
52 WEEK HIGH
17.85
52 WEEK LOW
2.910
MARKET CAP
86.51M
P/E (TTM)
-3.0544
1D
5D
1M
3M
1Y
5Y
PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced PDS Bio...
GlobeNewswire · 1d ago
PDS Biotech And National Cancer Institute Identify Optimal Patient Group For Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
FLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and
Benzinga · 4d ago
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a median of 12 monthsFLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB...
GlobeNewswire · 4d ago
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Compan...
GlobeNewswire · 09/06 12:00
PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has <a href="...
Seekingalpha · 08/24 20:29
BRIEF-PDS Biotechnology Corp Files For Mixed Shelf Of Up To $150 Million - SEC Filing
BRIEF-PDS Biotechnology Corp Files For Mixed Shelf Of Up To $150 Million - SEC Filing
Reuters · 08/24 20:06
PDS Biotechnology Files For Mixed-Securities Shelf Offering Of Up To $150M
-SEC Filing
Benzinga · 08/24 20:05
How Much Upside is Left in PDS Biotechnology (PDSB)? Wall Street Analysts Think 265%
The consensus price target hints at a 265.3% upside potential for PDS Biotechnology (PDSB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witn...
Zacks · 08/11 13:55
More
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is engaged in the developing a pipeline of molecularly targeted immunotherapies. The Company owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. It develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.